The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
- 3 March 2016
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 36 (10), 1490-1497
- https://doi.org/10.1111/liv.13107
Abstract
Background & Aims Several staging systems have been proposed for hepatocellular carcinoma (HCC). Among them, only the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging systems also recommend treatment modality. This study was designed to see whether BCLC and HKLC staging can guide treatment strategy, so analyzed whether patients survival is better for those who received recommended therapy by each staging system. Methods A total of 3515 treatment‐naïve, newly diagnosed HCC patients at a single centre were analyzed. Results Five‐year survival rates according to BCLC stages: 0 = 79.1%, A = 62.9%, B = 40.3%, C = 21.3% and D = 27.0%; 5‐year survival rates according to HKLC stages: I = 72.3%, IIa = 54.9%, IIb = 50.6%, IIIa = 21.3%, IIIb = 10.2%, IVa = 16.7%, IVb = 7.2%, Va = 47.1% and Vb = 11.3%. The C‐indices of the BCLC and HKLC staging systems were 0.708 and 0.732 respectively. Patient survival was better when patients received the recommended treatment in stages 0 or A; survival was worse if treatment began at stage B, C or D. For HKLC staging system, survival was better when patients received the recommended treatment in stages I, IIa, IIb, IIIa or Va but was worse when treatment began in stages IIIb, IVa, IVb or Vb. Conclusion Both the BCLC and HKLC staging systems effectively stratified patient prognosis, but neither could direct therapy for a large proportion of patients; for some stages, recommended therapy was associated with worse prognosis.This publication has 32 references indexed in Scilit:
- Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long‐term clinical outcomes of 1717 treatment‐naïve patients with hepatocellular carcinomaLiver International, 2012
- KASL Clinical Practice Guidelines: Management of chronic hepatitis BClinical and Molecular Hepatology, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- TNM seventh edition: What's new, what's changedCancer, 2010
- Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patientsEuropean Journal of Cancer, 2009
- Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer PatientsTransplantation Proceedings, 2009
- Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systemsAlimentary Pharmacology & Therapeutics, 2008
- Staging systems in hepatocellular carcinomaHPB, 2005
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999